CMND Insider Trading
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $323,857.80
Insider Selling (Last 12 Months): $117,933.29
Clearmind Medicine Share Price & Price History
Current Price: $1.62
Price Change: ▲ Price Increase of +0.01 (0.62%)
As of 07/27/2026 04:00 PM ET
Clearmind Medicine Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/16/2026 | Financial Lp Hrt | Major Shareholder | Sell | 22,139 | $3.31 | $73,280.09 | 81,353 |  |
| 6/15/2026 | Financial Lp Hrt | Major Shareholder | Sell | 3,183 | $3.32 | $10,567.56 | 103,492 | |
| 6/12/2026 | Financial Lp Hrt | Major Shareholder | Sell | 2,102 | $3.36 | $7,062.72 | 106,675 | |
| 6/11/2026 | Financial Lp Hrt | Major Shareholder | Sell | 225,191 | $0.12 | $27,022.92 | 1,838,075 | |
| 6/10/2026 | Financial Lp Hrt | Major Shareholder | Buy | 2,159,052 | $0.15 | $323,857.80 | 2,063,266 | |
Clearmind Medicine Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/5/2025 | AdvisorShares Investments LLC | 224,378 | $0.23M | 0.0% | +9.0% | 4.105% |  |
| 8/4/2025 | AdvisorShares Investments LLC | 205,933 | $0.18M | 0.0% | -6.8% | 4.823% | |
| 2/17/2025 | Citadel Advisors LLC | 38,158 | $53K | 0.0% | +115.2% | 0.894% | |
| 2/11/2025 | Virtu Financial LLC | 39,479 | $54K | 0.0% | N/A | 0.925% | |
| 8/8/2024 | AdvisorShares Investments LLC | 128,641 | $0.21M | 0.0% | +14.2% | 7.598% | |
| 7/24/2024 | Cornerstone Wealth Group LLC | 20,000 | $34K | 0.0% | N/A | 1.183% | |
| 2/14/2024 | AdvisorShares Investments LLC | 92,693 | $0.26M | 0.1% | -24.8% | 5.485% | |
| 11/13/2023 | Warberg Asset Management LLC | 220,000 | $35K | 0.0% | N/A | 3.143% | |
| 8/9/2023 | AdvisorShares Investments LLC | 123,257 | $58K | 0.0% | -19.6% | 1.761% | |
| 5/9/2023 | AdvisorShares Investments LLC | 153,257 | $0.18M | 0.1% | N/A | 2.189% | |
Data available starting January 2016
Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.
Read More on Clearmind Medicine
Volume
39,967 shs
Average Volume
1,066,147 shs
Market Capitalization
$1.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.74
Who are the company insiders with the largest holdings of Clearmind Medicine?
